May 2018 $5 M No. 4 $2 to $10 million 5
Clinical Ink, Inc.: Raise no. 4, May 2018 × Investors in this round 5 investors had bought by the notice of May 18, 2018: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M (amount offered: indefinite)
Smallest investment taken $2,651
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Edward S. Seguine, Jr. · Executive Officer, Director Matthew LaVern King · Director Michael LaVern Sorensen · Director Richard LaVern Malcolm · Director Roger LaVern Davenport · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Edward S. Seguine, Jr., Ceo. Source: SEC Form D, newest notice filed May 18, 2018. Read the notice at the SEC .
equity SEC Dec 2017 $2 M No. 3 Under $2 million 9
Clinical Ink, Inc.: Raise no. 3, Dec 2017 × Investors in this round 9 investors had bought by the notice of Dec 28, 2017: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $3 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Edward S. Seguine, Jr. · Executive Officer, Director · Chief Executive Officer Scott S. Miltenberger · Executive Officer · Chief Financial Officer Matt S. King · Director Phil S. Waugh · Director Richard S. Malcolm · Director Todd S. Foley · Director Tony S. Rosenberg · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Scott Miltenberger, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 28, 2017. Read the notice at the SEC .
debt, options SEC Mar 2015 $10 M Issued in a merger or acquisition $2 to $10 million 21
Clinical Ink, Inc.: Private sale, Mar 2015 × Investors in this round 21 investors had bought by the notice of Apr 7, 2015: 21 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $5 million to $25 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Douglas E. Pierce, Jr. · Executive Officer, Director, Promoter Edward S. Seguine · Executive Officer, Director, Promoter Joe RS Schmidt · Executive Officer Ansbert RS Gadicke · Director Brad RS Geesaman · Director Matt RS King · Director Morana RS Jovan-Embiricos · Director Philip RS Waugh, Jr. · Director Robert RS Kniejski · Director Todd RS Foley · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On a merger: “There was a merger of two entities and some stock was issued in connection with the merger. A new round of financing was also obtained in connection with the merger.”Signed by Douglas E. Pierce, Jr., President. Source: SEC Form D and 1 amendment, newest notice filed Apr 7, 2015. Read the notice at the SEC .
equity SEC Oct 2013 $1 M No. 2 Under $2 million 18
Clinical Ink, Inc.: Raise no. 2, Oct 2013 × Investors in this round 18 investors had bought by the notice of Oct 29, 2013: 17 accredited, 1 not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $4 M offered; $3 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Douglas E. Pierce, Jr. · Executive Officer, Director, Promoter Edward S. Seguine · Executive Officer, Director, Promoter Philip RS Waugh, Jr. · Director Robert H. Kniejski · Director Stephen H. Coltrin · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Douglas E. Pierce, Jr., President. Source: SEC Form D, newest notice filed Oct 29, 2013. Read the notice at the SEC .
equity SEC Nov 2011 $3 M No. 1 $2 to $10 million 9
Clinical Ink, Inc.: Raise no. 1, Nov 2011 × Investors in this round 9 investors had bought by the notice of Dec 8, 2011: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $4 M offered; $0 M still to sell
Smallest investment taken $50,000
What was sold equity
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in North Carolina People named in the notice Douglas E. Pierce, Jr. · Executive Officer, Director, Promoter Christopher H. Ramm · Director Michael E. Lester · Director Philip RS Waugh, Jr. · Director Edward S. Seguine, Jr. · Promoter Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Douglas E. Pierce, Jr., Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 8, 2011. Read the notice at the SEC .
equity SEC